GlaxoSmithKline (GSK) AI Stock Analysis

Compare

5,210 Followers

Top Page

GlaxoSmithKline

(NYSE:GSK)

Select Model

Neutral 67 (OpenAI - 5.2)

Rating:67Neutral

Price Target:

$64.00

▲(12.14% Upside)

Action:DowngradedDate:02/06/26

The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.

Positive Factors

Margin Strength

Sustained high gross margins and a 2025 uptick in operating/EBITDA margins support durable cash generation and funding for R&D and launches. Strong margins provide resilience to pricing pressure and help finance specialty pipeline investments over a multi-year horizon without immediate reliance on external capital.

Cash Generation & Returns

Consistently positive operating cash flow and material shareholder distributions show strong internal cash conversion. This cash engine underpins sustained dividend increases, buybacks, and strategic M&A while allowing continued R&D funding and balance sheet management across the next 2–5 years, assuming stable operations.

Specialty & Pipeline Momentum

Robust specialty growth, accelerated HIV uptake, and active clinical advancement create a durable revenue-growth engine and reduce reliance on legacy GenMed. Multiple approvals and pivotal starts increase the probability of medium-term launches and replacement of LOE impacts, strengthening long-term product mix and margins.

Negative Factors

Leverage

A consistently debt-funded capital structure (D/E >1) limits financial flexibility and heightens sensitivity to cash-flow shocks. Elevated leverage constrains capacity for large discretionary investments or rapid bolt-on M&A and increases refinancing and interest-rate exposure over the medium term unless sustained FCF improvement reduces net debt materially.

Vaccine Headwinds

Structural softness in key vaccine markets introduces revenue cyclicality and caps near-term top-line visibility. Slowing Shingrix uptake and Arexvy pressure reduce a historically high-margin segment's contribution, increasing reliance on specialty growth to sustain company-level revenue and margin targets over the next several years.

GenMed & Exclusivity Risk

Pricing pressures, IRA-related U.S. impacts and upcoming LOE in core regimens create a durable revenue downside risk for GenMed. Replacement depends on successful development and commercialization of long-acting HIV and other specialty assets; any delays or launch underperformance would pressure revenue mix and margin sustainability beyond the near term.

GlaxoSmithKline (GSK) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$113.35B

Dividend Yield3.41%

Average Volume (3M)6.22M

Price to Earnings (P/E)13.2

Beta (1Y)0.31

Revenue Growth5.97%

EPS Growth128.66%

CountryUS

Employees68,629

SectorHealthcare

Sector Strength45

IndustryDrug Manufacturers - General

Share Statistics

EPS (TTM)0.70

Shares Outstanding2,035,817,700

10 Day Avg. Volume5,575,982

30 Day Avg. Volume6,220,542

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)4.51

Price to Sales (P/S)2.31

P/FCF Ratio12.66

Enterprise Value/Market Cap0.88

Enterprise Value/Revenue3.06

Enterprise Value/Gross Profit4.22

Enterprise Value/Ebitda8.73

Forecast

1Y Price Target

$56.20

Price Target Upside-1.52% Downside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)4.82

Revenue Forecast (FY)$45.81B

GlaxoSmithKline Business Overview & Revenue Model

Company DescriptionGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

How the Company Makes MoneyGSK generates revenue primarily through the sale of prescription medicines, vaccines, and consumer healthcare products. Its key revenue streams include sales from its pharmaceutical division, which focuses on innovative medicines and specialty pharmaceuticals, and its vaccines division, which provides immunizations against various diseases. The consumer healthcare segment contributes additional revenue through over-the-counter products, including oral health, pain relief, and wellness items. GSK also engages in collaborations and partnerships with other pharmaceutical and biotechnology companies, allowing for shared development costs and enhanced market access. Significant partnerships with organizations for vaccine distribution, especially during global health crises, further bolster its earnings.

GlaxoSmithKline Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Breaks down revenue by different business segments, highlighting which areas drive the most sales and profitability, and indicating where the company might focus its strategic efforts.

Chart InsightsGSK's Specialty Medicines segment has emerged as a key growth driver, with recent earnings highlighting a 15% sales increase, aligning with its projected dominance by 2031. While the Vaccines segment also shows positive momentum with a 9% rise, challenges persist in China and supply chain costs. The company's strategic focus on R&D and successful FDA approvals bolster its long-term growth outlook, despite delayed product launches. GSK's robust cash generation supports continued investments and shareholder returns, positioning it well to reach the upper end of its 2025 financial guidance.

Data provided by:

The Fly

GlaxoSmithKline Earnings Call Summary

Earnings Call Date:Feb 04, 2026

(Q4-2025)

% Change Since: |

Next Earnings Date:Apr 29, 2026

Earnings Call Sentiment Positive

Overall the call was positive: GSK reported solid FY2025 financial results with strong cash generation, upgraded shareholder returns, robust specialty and HIV growth, multiple pipeline advances and R&D outputs (5 FDA approvals, 7 pivotal starts) and clear BD activity. Offsetting risks include vaccine softness in the U.S. and China inventory issues, product-specific launch execution challenges (BLENREP, ZEJULA), GenMed pricing/generic pressures, currency headwinds and one-off charges; however management provided explicit 2026 guidance (sales 3–5%, core op profit/EPS +7–9%) and articulated a plan to accelerate the pipeline and commercial execution which suggests the positives materially outweigh the negatives.

Q4-2025 Updates

Positive Updates

Strong Full-Year Financial Performance

Sales up 7% to more than GBP 32 billion; core operating profit up 11%; core EPS up 12%; operating margin improved by 110 basis points (reported margin 29.9% impacted by currency).

Robust Cash Generation and Capital Returns

Cash generated from operations GBP 8.9 billion (more than GBP 10 billion excluding Zantac); free cash flow GBP 4.0 billion (more than GBP 5.0 billion excluding Zantac); underlying free cash generation > GBP 8 billion before investments; shareholder distributions ~GBP 4 billion (dividend upgraded 2p to 66p declared; 2026 dividend guidance 70p, +6%); 93 million shares repurchased (avg price 1473) with remaining GBP 0.6 billion buyback to complete; net debt/EBITDA ~1.3x stable.

Specialty Medicines Driving Growth

Specialty medicines sales increased 17%; Respiratory Immunology & Inflammation +18% (Benlysta +22%; Nucala +15% and delivered $2 billion, marking 10th consecutive year of double-digit growth); Oncology: Jemperli +89%, Ojjaara +60%; BLENREP approved in 15 markets; Exdensur approved in U.S., U.K. and Japan. Company expects specialty sales to grow low double-digit in 2026.

HIV Franchise Momentum

HIV sales up 11% in FY2025 (U.S. +14%); Cabenuva grew 42% and now represents >75% U.S. uptake in the quarter; long-acting injectables accounted for >75% of growth and ~1/3 of U.S. sales; Aplitude (long-acting PrEP) grew 62%; guidance for HIV mid- to high-single-digit growth in 2026 and Q6M regimen selection planned mid-year with Phase II progression toward a 2028–2030 launch cadence.

Productive R&D and Pipeline Progress

Five FDA approvals in 2025 and seven new pivotal trial starts; several important programs advancing (Efimosfermin Phase III starts, Nebula planned, Bepirovirsen positive Phase III B‑WELL 1 & 2 readouts for chronic hepatitis B, KALM-2 last patient first visit for Camlipixant with mid-2026 Phase III data expected, DREAM trials and other pivotal starts planned); company plans ~10 pivotal starts in 2026 including >5 ADC pivotal starts and further oncology, MASH and HIV pivotal programs.

Active Business Development to Enhance Pipeline

Acquisition agreement to acquire Rapp Therapeutics (Ozureprubart, an anti-IgE for food allergy in Phase II); added 3 potentially best-in-class clinical-stage specialty assets via BD; continued focus on smart BD to accelerate portfolio value.

Negative Updates

Vaccine Market Headwinds and Mixed Performance

Vaccines sales up only 2% to GBP 9.2 billion; Shingrix up 8% driven by ex-U.S. and Japan but U.S. immunization rates slowing and partner-managed inventory in China weighing on growth; Arexvy up 2% but company expects low single-digit decline to stable in 2026; Shingrix U.S. momentum described as slowing.

GenMed Pressures and Pricing/Gx Risks

General Medicines slightly down for the year with TRELEGY growth offset by declines elsewhere; company expects GenMed sales to be in a low single-digit decline to stable in 2026 due to pricing pressures and generic competition; U.S. impact from Medicare redesign (Inflation Reduction Act) ran near the upper end of the GBP 400–500 million range.

Product-Specific Setbacks and Launch Execution Risks

ZEJULA sales decreased due to FDA labeling restrictions; BLENREP launch expected to be a slow ramp because of REMS requirements and the need to coordinate with eye-care professionals (account openings and care coordination are rate-limiting); Exdensur launch expected to be gradual despite strong clinical profile.

Currency and Margin Headwinds

Currency exposure flagged as a headwind: if rates hold at 28 Jan levels, expected impact of about -3% on sales and -6% on operating profit; currency lowered reported margin to 29.9% for the year despite underlying margin improvement.

One-off Costs and Ongoing Settlements

Zantac payments of GBP 1.2 billion in 2025 (GBP 1.9 billion total) and core Q4 charges of GBP 300 million (split evenly across supply chain and SG&A) to drive productivity were taken in 2025; these items affected cash flow and margin phasing.

Competitive & Exclusivity Risk in HIV Franchise

Dolutegravir loss of exclusivity (LOE) starts in 2028 creating a glide‑path risk to existing regimens; replacement via long-acting assets (Q4M and Q6M) is the intended mitigation but execution and timing are critical and carry uncertainty.

R&D Restructuring and Headcount Uncertainty

Reported reductions in R&D headcount (~350 people across U.S. and U.K. cited in Q&A) and comments on reallocating/simplifying resources imply potential execution and transition risk as the organisation shifts focus and redeploys staff/capital.

Company Guidance

GSK guided to another year of profitable growth for 2026, forecasting sales up 3–5% at constant exchange rates, core operating profit and core EPS each up 7–9%, and a 70p dividend (a 6% increase). By product area, specialty is expected to grow at a low double‑digit rate (HIV mid‑ to high‑single digit), while vaccines and GenMed are expected to be flat to a low single‑digit decline, with sales evenly phased through the year. On the P&L GSK expects low‑single‑digit SG&A growth, R&D to grow ahead of sales, continued gross‑margin benefit from the portfolio transition and supply‑chain efficiencies, and H2‑weighted operating‑profit delivery after GBP 300m of Q4’25 charges and the Q2 annualization of the RSV settlement; currency at 28 Jan rates could reduce sales by ~3% and operating profit by ~6%. The company reiterated cash strength—on track for >£10bn cash generation in 2026 (underlying free cash generation >£8bn pre‑decisions), free cash flow was £4bn in 2025 (£>5bn excl. Zantac), net debt/EBITDA ~1.3x—and noted £4bn of 2025 shareholder distributions (93m shares repurchased at an average price of 1,473 with £0.6bn of buyback remaining); taking midpoints of 2026 ranges implies c.8% sales and c.13% operating‑profit CAGR for 2021–2026.

GlaxoSmithKline Financial Statement Overview

Summary

Strong profitability (consistently high gross margins and improved operating/EBITDA margins in the latest period) and consistently positive operating cash flow/free cash flow. Offsetting factors are a leveraged capital structure (debt-to-equity >1.0), volatile reported earnings, weak/negative recent free-cash-flow growth (including a steep 2025 decline), and a sharp revenue drop in the most recent annual period.

Income Statement

Positive

Revenue has been relatively stable over the last few years, but the latest annual period shows a sharp decline (2025 vs. 2024). Profitability is a clear strength: gross margins are consistently strong (~67%–73%) and operating profitability improved materially in 2025 versus 2024 (higher operating and EBITDA margins). Net margin also rebounded in 2025 versus 2024, but earnings have been volatile across the period, including an outsized profit year in 2022 that suggests non-recurring dynamics and reduces perceived consistency.

Balance Sheet

Neutral

Leverage is the main constraint: debt-to-equity has remained above 1.0 in every year provided, indicating a meaningfully debt-funded capital structure. The trend improved versus the 2022 peak (when leverage was notably higher), supported by higher equity and lower debt versus earlier years. Returns on equity look strong in several years (especially 2025), but they are uneven and were exceptionally high in 2022, which can reflect one-time items and/or the impact of leverage rather than purely steady operating performance.

Cash Flow

Positive

Cash generation is solid in absolute terms, with operating cash flow and free cash flow consistently positive across the period. Free cash flow covered a good portion of earnings in most years (improving in 2025 versus 2024). However, free cash flow growth is weak/negative in recent years (including a steep decline in 2025), and operating cash flow covers only a modest share of total debt, implying limited near-term debt paydown capacity without sustained cash flow improvement.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	31.95B	31.38B	30.33B	29.32B	24.70B
Gross Profit	23.18B	22.33B	21.76B	19.77B	16.53B
EBITDA	11.62B	6.67B	9.08B	8.60B	6.49B
Net Income	5.59B	2.58B	4.93B	14.96B	4.38B
Balance Sheet
Total Assets	61.01B	59.46B	75.22B	60.15B	107.14B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.71B	6.61B	7.88B	5.87B
Total Debt	17.69B	16.99B	22.97B	20.99B	32.74B
Total Liabilities	45.02B	46.38B	58.91B	50.05B	78.23B
Stockholders Equity	16.35B	13.67B	17.01B	10.60B	20.39B
Cash Flow
Free Cash Flow	5.82B	3.57B	6.26B	6.75B	5.30B
Operating Cash Flow	7.14B	6.55B	7.89B	8.16B	7.95B
Investing Cash Flow	-5.72B	-1.23B	-2.40B	-10.88B	-1.78B
Financing Cash Flow	-1.59B	-4.73B	-6.07B	2.05B	-7.59B

GlaxoSmithKline Technical Analysis

Technical Analysis Sentiment

Positive

Last Price57.07

Price Trends

50DMA

52.95

Positive

100DMA

49.44

Positive

200DMA

44.00

Positive

Market Momentum

MACD

1.65

Positive

RSI

52.38

Neutral

STOCH

18.68

Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GSK, the sentiment is Positive. The current price of 57.07 is below the 20-day moving average (MA) of 58.56, above the 50-day MA of 52.95, and above the 200-day MA of 44.00, indicating a neutral trend. The MACD of 1.65 indicates Positive momentum. The RSI at 52.38 is Neutral, neither overbought nor oversold. The STOCH value of 18.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSK.

GlaxoSmithKline Risk Analysis

GlaxoSmithKline disclosed 1 risk factors in its most recent earnings report. GlaxoSmithKline reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

GlaxoSmithKline Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AZN	73 Outperform	£233.99B	28.13	22.34%	1.53%	10.20%	40.57%
AMGN	71 Outperform	$203.23B	22.84	106.10%	3.00%	11.03%	65.22%
BMY	71 Outperform	$124.67B	17.70	40.53%	4.84%	1.26%	―
SNY	69 Neutral	$111.60B	-31.42	6.76%	4.58%	-9.32%	120.62%
GSK	67 Neutral	$113.35B	13.19	38.48%	3.41%	5.97%	128.66%
PFE	64 Neutral	$151.37B	18.21	8.87%	6.65%	4.44%	128.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GSK

GlaxoSmithKline

56.83

19.51

52.26%

AMGN

Amgen

379.27

72.33

23.56%

BMY

Bristol-Myers Squibb

62.33

5.39

9.46%

PFE

Pfizer

26.62

2.44

10.07%

SNY

Sanofi

46.22

-11.10

-19.37%

GB:AZN

AstraZeneca

15,088.00

3,232.62

27.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 06, 2026